TICKERNOMICS Sign up
Last Update: 2024-03-28 02:13:39
LianBio ( LIAN ) https://www.lianbio.com
631.14USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
LIAN
38150.91%
SPY
32.74%
LIAN
0.00%
SPY
92.93%
LIAN
0.00%
SPY
224.41%
LIAN
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
67637.82
67491.89
0.00
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-768.78
0.00
286.46
-0.10
0.00
-659.70
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
-126.85
-39.43
0.00
Other Earnings and Cash Flow Stats:
LianBio ( LIAN ) Net Income TTM ($MM) is -88.26
LianBio ( LIAN ) Operating Income TTM ($MM) is -106.06
LianBio ( LIAN ) Owners' Earnings Annual ($MM) is 0.00
LianBio ( LIAN ) Current Price to Owners' Earnings ratio is 0.00
LianBio ( LIAN ) EBITDA TTM ($MM) is -104.81
LianBio ( LIAN ) EBITDA Margin is 0.00%
Capital Allocation:
LianBio ( LIAN ) has paid 0.00 dividends per share and bought back 0.75560499999999 million shares in the past 12 months
LianBio ( LIAN ) has reduced its debt by 1.496 million USD in the last 12 months
Capital Structure:
LianBio ( LIAN ) Interest-bearing Debt ($MM) as of last quarter is 2
LianBio ( LIAN ) Annual Working Capital Investments ($MM) are 29
LianBio ( LIAN ) Book Value ($MM) as of last quarter is 236
LianBio ( LIAN ) Debt/Capital as of last quarter is 1%
Other Balance Sheet Stats:
LianBio ( LIAN ) has 103 million in cash on hand as of last quarter
LianBio ( LIAN ) has 25 million of liabilities due within 12 months, and long term debt 0 as of last quarter
LianBio ( LIAN ) has 107 common shares outstanding as of last quarter
LianBio ( LIAN ) has 0 million USD of preferred stock value
Academic Scores:
LianBio ( LIAN ) Altman Z-Score is 1511.73 as of last quarter
LianBio ( LIAN ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
LianBio ( LIAN ) largest shareholder is LANDSCAPE CAPITAL MANAGEMENT,LLC owning 131641 shares at 83.08 ($MM) value
Perceptive Advisors Llc(an insider) Bought 998240 shares of LianBio ( LIAN ) for the amount of $2395776.00 on 2022-08-18
5.88% of LianBio ( LIAN ) is held by insiders, and 80.11% is held by institutions
LianBio ( LIAN ) went public on 2021-11-01
Other LianBio ( LIAN ) financial metrics:
FCF:-81.52
Unlevered Free Cash Flow:-133.77
EPS:-0.90
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-47.52
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About LianBio ( LIAN ) :
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.